Compassionate Care Solutions Provider Covalon Participating in the Canadian Vascular Access Association and World Congress on Vascular Access Joint Conference on April 26-28, 2023 in Toronto
MISSISSAUGA, ON, April 26, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its attendance at the 48th Annual Canadian Vascular Access Association (CVAA) Conference and World Congress on Vascular Access (WoCoVA) Special Event from Wednesday, April 26 to Friday, April 28, 2023 in Toronto, Canada.
CVAA is the only Canadian national conference that brings together infusion therapy and vascular access professionals in Canada. WoCoVA aims to improve vascular access for patients worldwide by promoting the science and practice of vascular access. Through the WoCoVA network, national societies like CVAA can share results of research, initiatives, and innovations in vascular access with other specialists from all over the globe.
"We are excited to participate in the CVAA Conference to share information and help educate how our suite of vascular access infection prevention solutions can help to improve the overall patient care experience," said Ron Hebert, Senior Vice President, Global Marketing, Covalon. "Our products are made for patients but have been specifically designed with the care providers that use them in mind."
Visit the Covalon booth to learn more about the company's vascular access and infection prevention solutions, and how Covalon is focused on compassionate care tech that benefits both patients and care providers. To schedule an appointment with a Covalon representative at this event, please email [email protected].
Conference Details
Dates: Wednesday, April 26 to Friday, April 28, 2023
Venue: Sheraton Centre Toronto Hotel (123 Queen St W, Toronto, Ontario, Canada)
Register at: https://cvaa.info/en/news-events/event-calendar/pageid/signuptoevent/eventid/337/e/48th-annual-cvaa-conference-wocova-special-event-26-apr-2023
Covalon's vascular access infection prevention solutions help to prevent central line-associated bloodstream infections (CLABSIs) as part of an effective CLABSI prevention bundle, while ensuring patient comfort and include:
- CovaClear® IV – utilizes soft silicone adhesive technology to help protect patients from skin injuries, but does not incorporate antimicrobials, for use with patients who either don't require or cannot tolerate antimicrobials.
- IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
- VALGuard® - an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
For healthcare providers who are not able to attend the conference but are interested in learning more about Covalon's solutions, visit www.covalon.com or follow Covalon on LinkedIn, Facebook, Instagram or Twitter.
Covalon Technologies Ltd. is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, we offer innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2022, which is available on the Company's profile at www.sedar.com, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
SOURCE Covalon Technologies Ltd.
To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: [email protected], Phone: 905.568.8400 x 233, Toll-Free: 1.877.711.6055, Website: https://covalon.com/, Twitter: @covalon
Share this article